IDH2 and astrocytoma (excluding glioblastoma): In a subsequent study, the same group examined its differential expression according to IDH status, and showed statistically significant lower mRNA expression in IDH‐mutant LGG of TCGA cohort in comparison to IDH‐wildtype, together with lower expression in IDH‐mutant GBM (current nomenclature is WHO grade IV IDH‐mutant astrocytoma) of TCGA, without statistical significance due to small number.